Drawing on decades of experience cultivated by the FormuRx Biotech team in the field of drug research and development, they have observed that startup or small biotechnology and pharmaceutical companies, in order to accelerate profitability or secure the funding required for clinical trials, often ignore or simplify the needs of drug formulation development in the early stages. For instance, they fail to evaluate early on the physicochemical properties of the drug, the compliance and safety of material selection, the clinical route of administration and its subsequent impact on efficacy, and even the mass-producibility of the finished product. These closely linked challenges often lead to setbacks in the clinical trial process, thereby hindering the commercialization of the product and resulting in massive investment losses. If all of these issues could be squarely addressed through the precise optimization of formulations during the initial preclinical trial stage, the massive losses subsequently caused by formulation and recipe issues could be largely avoided. To this end, FormuRx takes "Begin with the End in Mind" as its core corporate philosophy, injecting drug delivery system technology into modern precision therapy to precisely optimize the biopharmaceutical industry value chain. This precision therapy covers the following points to enhance the value of drugs:
(The content above was translated by AI.)